NYSE:EBS - Emergent Biosolutions Stock Price, Price Target & More

Emergent Biosolutions trades on the New York Stock Exchange (NYSE) under the ticker symbol "EBS."

Emergent Biosolutions announced that its Board of Directors has authorized a stock buyback program on Friday, March 23rd 2018, which permits the company to repurchase $50,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to purchase shares of its stock through open market purchases. Shares repurchase programs are usually an indication that the company's leadership believes its shares are undervalued.

Emergent Biosolutions Inc (NYSE:EBS) announced its quarterly earnings data on Thursday, May, 3rd. The biopharmaceutical company reported ($0.03) EPS for the quarter, missing analysts' consensus estimates of $0.22 by $0.25. The biopharmaceutical company earned $117.80 million during the quarter, compared to the consensus estimate of $140.42 million. Emergent Biosolutions had a return on equity of 10.39% and a net margin of 11.96%. The company's revenue for the quarter was up .8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.23 earnings per share. View Emergent Biosolutions' Earnings History.

Emergent Biosolutions is scheduled to release their next quarterly earnings announcement on Thursday, August, 2nd 2018. View Earnings Estimates for Emergent Biosolutions.

6 Wall Street analysts have issued 1 year price targets for Emergent Biosolutions' stock. Their predictions range from $53.00 to $62.00. On average, they anticipate Emergent Biosolutions' share price to reach $58.00 in the next twelve months. This suggests a possible upside of 7.6% from the stock's current price. View Analyst Ratings for Emergent Biosolutions.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Emergent Biosolutions in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Some companies that are related to Emergent Biosolutions include Alnylam Pharmaceuticals (ALNY), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Genmab A/S (GNMSF), Sarepta Therapeutics (SRPT), Beigene (BGNE), Nektar Therapeutics (NKTR), Valeant Pharmaceuticals (VRX), SAGE Therapeutics (SAGE), Alkermes (ALKS), Catalent (CTLT), Ionis Pharmaceuticals (IONS), Dr.Reddy's Laboratories (RDY), United Therapeutics (UTHR) and Loxo Oncology (LOXO).

News headlines about EBS stock have been trending somewhat negative recently, Accern Sentiment reports. The research group identifies positive and negative news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Emergent Biosolutions earned a daily sentiment score of -0.04 on Accern's scale. They also gave news coverage about the biopharmaceutical company an impact score of 43.63 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near term.

Emergent Biosolutions' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Fisher Asset Management LLC (0.71%), Peregrine Capital Management LLC (0.66%), Bank of Montreal Can (0.14%), First National Bank of Omaha (0.02%), Xact Kapitalforvaltning AB (0.02%) and Capital Asset Advisory Services LLC (0.02%). Company insiders that own Emergent Biosolutions stock include Adam Havey, Daniel Abdun-Nabi, Fuad El-Hibri, George A Joulwan, Jerome M Hauer, Kathryn C Zoon, Ronald Richard, Sue Bailey and Zsolt Harsanyi. View Institutional Ownership Trends for Emergent Biosolutions.

EBS stock was sold by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC, Bank of Montreal Can, Peregrine Capital Management LLC and Capital Asset Advisory Services LLC. Company insiders that have sold Emergent Biosolutions company stock in the last year include Adam Havey, Daniel Abdun-Nabi, Fuad El-Hibri, George A Joulwan, Jerome M Hauer, Kathryn C Zoon, Ronald Richard and Zsolt Harsanyi. View Insider Buying and Selling for Emergent Biosolutions.

EBS stock was purchased by a variety of institutional investors in the last quarter, including First National Bank of Omaha and Xact Kapitalforvaltning AB. View Insider Buying and Selling for Emergent Biosolutions.

Shares of EBS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of EBS stock can currently be purchased for approximately $53.91.

Emergent Biosolutions has a market capitalization of $2.74 billion and generates $560.87 million in revenue each year. The biopharmaceutical company earns $82.59 million in net income (profit) each year or $1.90 on an earnings per share basis. Emergent Biosolutions employs 1,256 workers across the globe.

Emergent Biosolutions' mailing address is 400 PROFESSIONAL DR SUITE 400, GAITHERSBURG MD, 20879. The biopharmaceutical company can be reached via phone at 240-631-3200 or via email at [email protected]